Developent and Implement a Method of Parkinson's Disease Therapy Using Cell Technology
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- signs of depression change
研究概览
简要总结
Treatment of patients with Parkinson's disease using mesenchymal stem cells is a perspective method to influence on the pathogenesis of the disease. At the same time, this is a complex and still insufficiently explored process. Autologous mesenchymal stem cells will be transplanted to 30 patients with Parkinson's disease. The results of the effectiveness of the combined and intravenous routes of mesenchymal stem cells administration on the motor and non-motor symptoms in these patients will be evaluated and compared with the results of control group that received placebo therapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A reliable diagnosis of Parkinson's disease, according to the diagnostic criteria developed by the Brain Bank of the Society for Parkinson's disease of Great Britain (UK Brain Bank Criteria, 1992).
- •Stage of the disease according to Hen-Yar: 1.5 - 3.0 stage.
- •Rapidly progressive type with a change in the stages of Parkinson's disease in no more than 4 years.
- •A good response to levodopa treatment: a positive dopamine test for assessing motor functions by a total score of section 3 of the UPDRS scale in the on- and off-period (not less than 30%).
- •The duration of the disease is not more than 8 years with the absence of motor fluctuations and dyskinesias.
- •The age of patients is up to 65 years
排除标准
- •e and parkinsonism-plus.
- •Severe concomitant diseases (congestive heart failure, myocardial infarction, pneumonia, decompensated diabetes mellitus, cachexia, etc.).
- •Autoimmune diseases, a tendency to bleeding, a history of sepsis.
- •Oncological diseases.
- •The presence of acute or exacerbation of the chronic inflammatory process of the sinuses or oral cavity.
- •A positive result for HIV, hepatitis B (HBV), hepatitis C (HCV), syphilis (RW).
- •Cognitive deficit.
- •Mental disorders - hallucinations, behavior disorders.
- •Depression of a pronounced degree (not more than 19 points on the Hamilton scale).
- •Alcoholism, drug addiction, criminal liability in the patient's history.
- •Pregnancy, lactation.
结局指标
主要结局
signs of depression change
时间窗: 3 month
We use the Hamilton Depression Scale - Hamilton psychiatric rating scale for depression (HDRS) - to identify signs of depression. A score of 52 represents the worst result with a score of zero representing (no disability).
motor symptoms change
时间窗: 3 month
Positive trend is going to be detected in the overall score of the third part of the UPDRS scale(Unified Parkinson Disease Rating Scale) in the off- and in the on-period:neurological examination of patients in the dynamics is carried out in the morning after a 12 (24) - hour break in taking anti-Parkinsonian drugs "off-state", then one hour after they were taken "on-state". A score of 64 on the third part of the UPDRS scale represents the worst (total motor disability) with a score of zero representing (no disability).
non-motor symptoms change
时间窗: 3 month
Identification and assessment of the severity of non-motor symptoms is carried out using Non-motor Symptoms Questionnaire (PD NMS Questionnaire).A score of 30 represents the worst result with a score of zero representing (no disability).
sleep quality change
时间窗: 3 month
The Pittsburgh Sleep Quality Index (PSQI) is used to assess sleep quality over the last month.The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.
daytime sleepiness change
时间窗: 3 month
The Epworth Sleepiness Scale (ESS) is used to measure daytime sleepiness.The ESS score can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.
次要结局
未报告次要终点